Drug intelligence / Profile preview

IK-01

Development stage: Unknown
Lead developer: CynosBio
Modality: Cell Therapies
Administration: Implant

Overview

IK-01 is an autologous human cartilage cell processed product developed by Hirosaki Lifescience Innovation, Inc. for the treatment of focal knee cartilage injuries and osteochondritis dissecans. The therapy involves the transplantation of the patient's own processed chondrocytes into cartilage defects to promote tissue regeneration and repair. It is currently being evaluated in a Phase 3 clinical trial in Japan, where its efficacy and safety are being compared against microfracture surgery, a standard-of-care surgical technique for cartilage repair.

Other names: autologous human cartilage cell processed product

Beyond the preview

Go deeper on IK-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IK-01.

Explore the full profile